Correspondence

RANDAL R. JONES
(206) 903-8814
FAX (206) 903-8820
JONES.RANDAL@DORSEY.COM

June 26, 2009

Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-7010

Re: OncoGenex Pharmaceuticals — Registration Statement on Form S-3 (File No. 333-160251) filed on June 26, 2009

Dear Sir or Madam,

In connection with the Registration Statement on Form S-3 (file no. 333-160251) filed on June 26, 2009 by OncoGenex Pharmaceuticals, Inc., we are furnishing the correspondence attached as Exhibit A required under National Instrument 71-101.


	Very truly yours,
	/s/ Randal R. Jones
	Randal R. Jones

NOTICE OF FILING PURSUANT TO NATIONAL INSTRUMENT 71-101
The Multijurisdictional Disclosure System


TO:		British Columbia Securities Commission

AND TO:		The United States Securities and Exchange Commission

RE:		OncoGenex Pharmaceuticals, Inc. (the “Company”)

The Company has today filed a preliminary MJDS prospectus dated June 26, 2009, pursuant to National Instrument 71-101, The Multijurisdictional Disclosure System (“NI 71-101”), and designates the British Columbia as the principal jurisdiction in Canada.

DATED June 26, 2009.

ONCOGENEX PHARMACEUTICALS, INC.


/s/ Scott Cormack Scott Cormack
President and Chief Executive Officer